1. Home
  2. PWP vs TSHA Comparison

PWP vs TSHA Comparison

Compare PWP & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perella Weinberg Partners

PWP

Perella Weinberg Partners

N/A

Current Price

$17.23

Market Cap

1.2B

Sector

Finance

ML Signal

N/A

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

N/A

Current Price

$4.13

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PWP
TSHA
Founded
2006
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PWP
TSHA
Price
$17.23
$4.13
Analyst Decision
Hold
Strong Buy
Analyst Count
3
9
Target Price
$23.50
$10.78
AVG Volume (30 Days)
745.3K
2.5M
Earning Date
05-01-2026
03-19-2026
Dividend Yield
1.65%
N/A
EPS Growth
138.52
5.56
EPS
0.47
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
$31.87
N/A
Revenue Next Year
$17.04
$637.76
P/E Ratio
$36.17
N/A
Revenue Growth
N/A
17.28
52 Week Low
$14.44
$1.13
52 Week High
$25.93
$6.02

Technical Indicators

Market Signals
Indicator
PWP
TSHA
Relative Strength Index (RSI) 41.81 36.83
Support Level $17.05 $4.03
Resistance Level $19.49 $5.16
Average True Range (ATR) 0.76 0.23
MACD 0.13 -0.02
Stochastic Oscillator 52.81 9.38

Price Performance

Historical Comparison
PWP
TSHA

About PWP Perella Weinberg Partners

Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: